The Menopause Transition Protocol: Building Non-Hormonal Support in Layers

Key Takeaways

There are two ways to build a menopause supplement stack.

The common way starts with the symptom that hurts: buy a hot-flush herb, add a second one when the first disappoints, and get to bone eventually or never. The evidence-ordered way starts with the intervention that has the best data and the narrowest window — which happens to be the one that produces no felt effect whatsoever.

This is the second version. It is deliberately non-hormonal, deliberately layered, and deliberately explicit about which tiers are strong and which are not.

Before Anything: The Sentence That Has to Come First

Hormone therapy is the most effective treatment for vasomotor symptoms. The 2023 nonhormone therapy position statement of The North American Menopause Society says so, and recommends it be considered for women within ten years of their final menstrual period.

The same statement does not recommend supplements or herbal remedies for vasomotor symptoms — including soy foods, soy extracts and equol. Its Level I non-hormonal recommendations are cognitive-behavioural therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin, and fezolinetant.

If none of that has been discussed with a clinician, that conversation outranks this protocol. What follows is for the woman who has a contraindication, has declined hormone therapy, or has worked through the recommended options and wants the best supplement layer with honest labels on every tier.

The Layer Map

The protocol as a whole is graded C, to its weakest load-bearing claim. Layer 0 alone is a solid B.

Layer 0 — Start Here, and Start Early

This is the layer with the real argument behind it, and the argument is about timing.

In the SWAN multiethnic cohort, bone mineral density loss began one year before the final menstrual period and decelerated — without ceasing — two years after it. Across ten years, cumulative lumbar spine loss was 10.6%, and 7.38% of that occurred inside the three-year transmenopausal window. Femoral neck loss: 9.1% cumulative, 5.8% in the same window.

About 70% of a decade's spinal bone loss happens in three years, and those three years begin while you are still menstruating.

A woman who defers bone until "after menopause" has, by definition, deferred it past the part that mattered. And because the final menstrual period is only identifiable twelve months retrospectively, there is no way to time this precisely — which argues for starting when cycles first become irregular, the early-transition marker in the STRAW+10 staging framework.

The components

Dose D3 to a 25(OH)D of 30–50 ng/mL and retest at 8–12 weeks — to a level, not a pill count. The calcium-routing logic is developed in full in The Bone & Arterial Longevity Protocol.

⚠️ K2 and warfarin do not mix without prescriber management.

The evening magnesium is not filler. Sleep fragmentation is frequently rated as more disabling than the flushes themselves, and magnesium is doing double duty as the vitamin D cofactor and the sleep component.

Layer 1 — One Agent, Twelve Months

Two rules govern this layer, and both come from trial data rather than preference.

Rule 1: Choose one

Do not run isoflavones and black cohosh together. In the HALT trial — 351 women, twelve months, five arms — the multibotanical-plus-soy arm produced vasomotor symptom intensity significantly worse than placebo at 12 months (P = 0.016). No herbal arm beat placebo at any timepoint.

That is a measured downside to layering, not a theoretical one. Pick one, run it properly, then switch if it fails.

Rule 2: Twelve months, not twelve weeks

Model-based meta-analysis of 16 isoflavone trials found half-maximal effect at 13.4 weeks against 3.09 weeks for estradiol, and roughly 48 weeks to reach 80% of maximum. The authors stated plainly that twelve-week treatment intervals are too short.

Most trials ran twelve weeks. So do most self-experiments. Stopping at three months means stopping at the halfway mark and calling it a failure.

Option A — Soy isoflavones (preferred)

60 mg total isoflavones daily with food (range 40–100 mg). Buy on stated total isoflavone milligrams, not "soy extract mg."

Expected effect, stated honestly: maximum 25.2% hot-flash reduction after subtracting placebo — about 57% of estradiol's 44.9% ceiling. Real, modest, slow.

The equol caveat. Only about a third of Western women convert daidzein into S-equol. In one study of 365 midlife women, 129 (35%) were producers; among them, the highest quartile of daidzein intake carried 76% lower odds of above-average vasomotor symptoms (OR 0.24; 95% CI 0.07–0.83). Among non-producers, no association at all.

If twelve months of isoflavones does nothing, non-producer status is the most likely explanation. The workaround is direct S-equol at 10–30 mg/day — whose best-supported effects are on mood-related outcomes (tension-anxiety, depression-dejection, fatigue, vigour) rather than flush counts.

Isoflavones also carry the steadiest signal in this whole protocol for bone: meta-analyses report preserved lumbar spine density and lower resorption markers. That makes them the one Layer 1 agent that also reinforces Layer 0.

Separate from levothyroxine by at least four hours.

Option B — Black cohosh (weaker)

40 mg/day of the isopropanolic extract (iCR) — the preparation actually used in the more positive trials. Ethanolic extracts and root powder are chemically different products and their evidence does not transfer.

Expected effect, stated honestly: Cochrane pooled 16 trials and 2,027 women and found a difference from placebo of 0.07 hot flushes per day (95% CI −0.43 to 0.56, P = 0.79). Individual iCR trials have been more favourable, which is why this option exists at all rather than being deleted.

Liver monitoring is the price of entry. The EU mandates a liver-reaction warning. A meta-analysis of five trials in 1,117 women found no effect of iCR on AST or ALT, but controlled trials cannot detect a rare idiosyncratic reaction. Check transaminases at baseline and three months, and stop immediately at jaundice, dark urine, right upper quadrant pain, or unexplained fatigue.

Layer 2 — Optional, and Labelled As Such

DIM and calcium-D-glucarate work opposite ends of the same pipeline: DIM shifts phase I metabolism toward 2-hydroxyestrone, calcium-D-glucarate inhibits gut beta-glucuronidase so conjugated oestrogen is excreted rather than reabsorbed.

DIM — 150 mg/day, absorption-enhanced form, with a fat-containing meal. A 12-month randomised trial raised the 2:16 ratio significantly against placebo and lifted SHBG by about 25 nmol/L. The same trial found no change in breast density, and exposure plateaus above 200 mg, so there is no case for escalating.

⚠️ DIM is contraindicated on tamoxifen — that trial found significantly reduced plasma endoxifen and other tamoxifen metabolites.

Calcium-D-glucarate — 1,500 mg/day split across meals. Grade D: the supporting literature is rodent chemoprevention work from 1984–1997, with no human efficacy trial. Cheap, safe, coherent, unproven. Skipping it costs nothing you can demonstrate.

The full argument for both is in Estrogen Metabolism: DIM and Calcium-D-Glucarate Explained.

The Twelve-Month Schedule

Weeks 0–2 — Baseline. 25(OH)D, lipids and ApoB, TSH, ALT/AST if black cohosh is planned. DXA if in perimenopause. Start a weekly symptom diary — flush count, night waking, sleep quality, mood. Begin Layer 0.

Weeks 2–4 — Layer 0 only. Establish tolerance and habit before adding anything.

Week 4 — Add ONE Layer 1 agent. Isoflavones unless there is a reason to prefer black cohosh.

Week 12 — First checkpoint. Retest 25(OH)D and adjust D3. Retest ALT/AST if on black cohosh. Do not judge Layer 1 yet — you are at the half-maximal timepoint. Optionally add Layer 2 here.

Weeks 12–48 — Run it. Keep the diary weekly. Memory is not a measuring instrument for a slow, fluctuating symptom.

Week 48 — The real decision point. Compare the diary against baseline, not against how you feel today.

• Meaningful improvement → continue; reassess annually.
• Nothing on isoflavones → likely non-producer. Switch to S-equol 10–30 mg/day for a further six months, or move to the exit criteria.
• Nothing on black cohosh → do not add isoflavones on top. Switch, or exit.

Exit Criteria — Decide These Now

Write these down at week 0, so the decision is not made later by sunk cost.

• Symptoms still disrupting sleep or work after twelve months of Layer 1
• Symptoms began in early perimenopause — median total duration in that group exceeds 11.8 years, which is a very long time to spend on a 25% intervention
• Low bone density on DXA, or any fragility fracture
• Genitourinary symptoms — vaginal dryness, pain, urinary symptoms. Nothing in this protocol treats these; local vaginal oestrogen does, at negligible systemic exposure
• Any abnormal bleeding — this needs a diagnosis, not a supplement

Meeting any of these means the supplement route has been given a fair run and the conversation moves to hormone therapy or the Level I non-hormonal options.

What This Protocol Deliberately Excludes

• Multi-botanical "hormone balance" blends — undisclosed doses, and usually the exact phytoestrogen-plus-black-cohosh pairing HALT flagged
• Hormonal precursors — DHEA and pregnenolone are a different approach with different risks, requiring bloodwork and clinician oversight. That protocol is Female Hormonal Optimization, and it is an alternative to this one, not an extension of it
• A single FSH test to "confirm" perimenopause — staging is by cycle pattern under STRAW+10, not one blood draw in a phase of wide hormonal swings

For the broader longevity layer that sits alongside this across the whole midlife decade — NAD+, cardiovascular, cognitive — see The Female Longevity Stack.

Frequently Asked Questions

Can I take Layer 0 alongside hormone therapy?

Yes. Layer 0 contains no hormones and no phytoestrogens — it is vitamin D, vitamin K2 and magnesium, and it is appropriate regardless of what you take for symptoms. Layer 1 and Layer 2 alongside HRT are a prescriber question, since both complicate titration.

Why is bone the mandatory layer if I feel fine?

Because feeling fine is exactly the problem. Bone loss is silent, it is fastest in a three-year window that opens before your last period, and roughly 70% of a decade's spinal loss happens inside it. It is the one part of this protocol with a closing window.

What if I want to try both isoflavones and black cohosh?

Sequentially, not together. HALT's soy-plus-multibotanical arm was significantly worse than placebo at twelve months. Run one for 48 weeks, then switch if it failed.

Is this protocol safe with a history of breast cancer?

It requires oncological supervision, not a purchase decision. DIM is contraindicated on tamoxifen. Phytoestrogens in survivors are a genuine clinical conversation with reassuring but not definitive observational data. Layer 0 is the only tier that is uncontroversial.

How much of this is placebo?

Possibly a good deal of Layer 1 — that is what the pooled data suggest, and it is why the honest framing is a modest expected effect rather than a promise. Layer 0 is not symptomatic and is not judged by how you feel, which is precisely why it is the mandatory tier.

Related Research

• The Menopause Transition Protocol
• Perimenopause Supplements: What the Evidence Actually Supports
• Estrogen Metabolism: DIM and Calcium-D-Glucarate Explained
• The Bone & Arterial Longevity Protocol